T1	intervention 0 20	Eribulin monotherapy
T3	total-participants 827 830	827
T4	age 38 56	70 years and older
T5	control-participants 886 889	253
T6	control-participants 908 911	289
T7	control-participants 930 933	206
T8	intervention-participants 951 953	79
T9	outcome 989 991	OS
T10	cv-cont-median 993 1004	11.8 months
T11	cv-cont-median 1006 1017	12.3 months
T12	cv-cont-median 1019 1030	11.7 months
T13	iv-cont-median 1036 1047	12.5 months
T14	outcome 1073 1076	PFS
T15	cv-cont-median 1078 1088	3.5 months
T16	cv-cont-median 1090 1100	2.9 months
T17	cv-cont-median 1102 1112	3.8 months
T18	iv-cont-median 1118 1128	4.0 months
T19	outcome 1154 1157	ORR
T20	outcome 1208 1211	CBR
T21	cv-cont-median 1159 1164	12.7%
T22	cv-cont-median 1166 1171	12.5%
T23	cv-cont-median 1173 1177	6.3%
T24	iv-bin-percent 1183 1188	10.1%
T25	cv-cont-median 1213 1218	20.2%
T26	cv-cont-median 1220 1225	20.8%
T27	cv-cont-median 1227 1232	20.4%
T28	iv-bin-percent 1238 1243	21.5%
T29	outcome 1388 1404	incidence of AEs
